Quidel Preliminary Q4 Revenues Down on Weak Flu Season | GenomeWeb

NEW YORK (GenomeWeb) – Quidel today reported preliminary revenues for the fourth quarter of 2015 well below analyst forecasts.

Due to a weak influenza season, the firm now expects Q4 revenues between $52 million and $53 million, below analysts' consensus estimate of $64 million.

Investors reacted negatively to the news, sending Quidel's shares down around 7 percent to $17.67 in mid-morning trade on the Nasdaq. The shares had fallen to as low as $16.71 earlier in the session.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.